Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 5 (2008), Issue 9 (September)

1. Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer.
   Cancer Res, 68(17): 7165-75. [Abstract] [Full-text]
2. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
   Lancet Oncol, 9(9): 840-9. [Abstract] [Full-text]
3. The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families.
   Cancer Res, 68(17): 7006-14. [Abstract] [Full-text]
4. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
   Lancet Oncol, 9(9): 866-72. [Abstract] [Full-text]
5. Specific increase of human kallikrein 4 mRNA and protein levels in breast cancer stromal cells.
   Biochem Biophys Res Commun, 375(1): 107-12. [Abstract] [Full-text]
6. Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stability.
   BMC Genomics, 9: 375. [Abstract] [Full-text]
7. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis.
   J Clin Oncol, 26(25): 4078-85. [Abstract] [Full-text]
8. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer.
   J Clin Oncol, 26(25): 4072-7. [Abstract] [Full-text]
9. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.
   J Clin Oncol, 26(25): 4063-71. [Abstract] [Full-text]
10. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.
    J Clin Oncol, 26(25): 4092-9. [Abstract] [Full-text]
11. Breast cancer onset in twins and women with bilateral disease.
    J Clin Oncol, 26(25): 4086-91. [Abstract] [Full-text]
12. Filamin A is a novel caveolin-1-dependent target in IGF-I-stimulated cancer cell migration.
    Exp Cell Res, 314(15): 2762-73. [Abstract] [Full-text]
13. Long-term population-based risks of breast cancer after childhood cancer.
    Int J Cancer, 123(9): 2156-63. [Abstract] [Full-text]
14. Tissue culture-based breast cancer biomarker discovery platform.
    Int J Cancer, 123(9): 2007-12. [Abstract] [Full-text]
15. Effect of obesity and other lifestyle factors on mortality in women with breast cancer.
    Int J Cancer, 123(9): 2188-94. [Abstract] [Full-text]
16. Bioelectrical impedance phase angle as a prognostic indicator in breast cancer.
    BMC Cancer, 8(1): 249. [Abstract] [Full-text]
17. Breast cancer, psychological distress and life events among young women.
    BMC Cancer, 8(1): 245. [Abstract] [Full-text]
18. Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response.
    Clin Cancer Res, 14(17): 5555-64. [Abstract] [Full-text]
19. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase.
    Clin Cancer Res, 14(17): 5459-65. [Abstract] [Full-text]
20. Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression.
    Clin Cancer Res, 14(17): 5357-67. [Abstract] [Full-text]
21. Influence of cellular ERalpha/ERbeta ratio on the ERalpha-agonist induced proliferation of human T47D breast cancer cells.
    Toxicol Sci, 105(2): 303-11. [Abstract] [Full-text]
22. Specific 50'CpG island methylation signatures of FHIT and p16 genes and their potential diagnostic relevance in Indian breast cancer patients.
    DNA Cell Biol, 27(9): 517-25. [Abstract] [Full-text]
23. Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab.
    Mol Cell Biol, 28(18): 5605-20. [Abstract] [Full-text]
24. A cautionary note on the evaluation of biomarkers of subtypes of a single disease.
    Am J Epidemiol, 168(6): 559-62. [Abstract] [Full-text]
25. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype.
    Hum Pathol, 39(10): 1431-7. [Abstract] [Full-text]
26. Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer.
    J Clin Oncol, 26(26): 4289-95. [Abstract] [Full-text]
27. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
    J Clin Oncol, 26(26): 4282-8. [Abstract] [Full-text]
28. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.
    Biochem J, 415(1): 97-110. [Abstract] [Full-text]
29. Histopathological findings and follow-up after prophylactic mastectomy and immediate breast reconstruction in 100 women from families with hereditary breast cancer.
    Eur J Surg Oncol, 34(10): 1148-54. [Abstract] [Full-text]
30. Outcomes of bilateral mammoplasty for early stage breast cancer.
    Eur J Surg Oncol, 34(10): 1143-7. [Abstract] [Full-text]
31. Refinement of breast cancer classification by molecular characterization of histological special types.
    J Pathol, 216(2): 141-50. [Abstract] [Full-text]
32. Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles.
    Oncogene, 27(40): 5359-72. [Abstract] [Full-text]
33. Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells.
    Biochem Biophys Res Commun, 375(3): 308-14. [Abstract] [Full-text]
34. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.
    Science, 321(5895): 1499-502. [Abstract] [Full-text]
35. Distinct karyotypes in three breast cancer cell lines --21PTCi, 21NTCi, and 21MT-1 --derived from the same patient and representing different stages of tumor progression.
    Cancer Genet Cytogenet, 186(1): 33-40. [Abstract] [Full-text]
36. Cutaneous vasculitis in breast cancer treated with chemotherapy.
    Clin Immunol, 129(1): 3-9. [Abstract] [Full-text]
37. Comparative evaluation of trace metal distribution and correlation in human malignant and benign breast tissues.
    Biol Trace Elem Res, 125(1): 30-40. [Abstract] [Full-text]
38. Giant phyllodes tumour of the breast.
    J Plast Reconstr Aesthet Surg, 61(10): e9-11. [Abstract] [Full-text]
39. Aesthetic outcome, patient satisfaction, and health-related quality of life in women at high risk undergoing prophylactic mastectomy and immediate breast reconstruction.
    J Plast Reconstr Aesthet Surg, 61(10): 1177-87. [Abstract] [Full-text]
40. Preservation of nipple-areola complex in breast cancer--a clinicopathological assessment.
    J Plast Reconstr Aesthet Surg, 61(10): 1195-8. [Abstract] [Full-text]
41. Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo.
    Cancer Res, 68(18): 7661-9. [Abstract] [Full-text]
42. CCN5/WISP-2 expression in breast adenocarcinoma is associated with less frequent progression of the disease and suppresses the invasive phenotypes of tumor cells.
    Cancer Res, 68(18): 7606-12. [Abstract] [Full-text]
43. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
    Cancer Res, 68(18): 7493-501. [Abstract] [Full-text]
44. Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells.
    Cancer Res, 68(18): 7304-12. [Abstract] [Full-text]
45. Association of common PALB2 polymorphisms with breast cancer risk: a case-control study.
    Clin Cancer Res, 14(18): 5931-7. [Abstract] [Full-text]
46. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients.
    Clin Cancer Res, 14(18): 5913-8. [Abstract] [Full-text]
47. Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer.
    Clin Cancer Res, 14(18): 5893-9. [Abstract] [Full-text]
48. Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.
    Clin Cancer Res, 14(18): 5864-8. [Abstract] [Full-text]
49. Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer.
    Clin Cancer Res, 14(18): 5849-55. [Abstract] [Full-text]
50. High-throughput screening identifies cardiac glycosides as potent inhibitors of human tissue kallikrein expression: implications for cancer therapies.
    Clin Cancer Res, 14(18): 5778-84. [Abstract] [Full-text]
51. Evaluation of multiple breathing states using a multiple instance geometry approximation (MIGA) in inverse-planned optimization for locoregional breast treatment.
    Int J Radiat Oncol Biol Phys, 72(2): 610-6. [Abstract] [Full-text]
52. The observed variance between predicted and measured radiation dose in breast and prostate patients utilizing an in vivo dosimeter.
    Int J Radiat Oncol Biol Phys, 72(2): 597-604. [Abstract] [Full-text]
53. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer.
    Int J Radiat Oncol Biol Phys, 72(2): 474-84. [Abstract] [Full-text]
54. Preliminary results of electron intraoperative therapy boost and hypofractionated external beam radiotherapy after breast-conserving surgery in premenopausal women.
    Int J Radiat Oncol Biol Phys, 72(2): 485-93. [Abstract] [Full-text]
55. How to boost the breast tumor bed? A multidisciplinary approach in eight steps.
    Int J Radiat Oncol Biol Phys, 72(2): 494-500. [Abstract] [Full-text]
56. Cardiac dose from tangential breast cancer radiotherapy in the year 2006.
    Int J Radiat Oncol Biol Phys, 72(2): 501-7. [Abstract] [Full-text]
57. Association between tangential beam treatment parameters and cardiac abnormalities after definitive radiation treatment for left-sided breast cancer.
    Int J Radiat Oncol Biol Phys, 72(2): 508-16. [Abstract] [Full-text]
58. A Phase II trial of brachytherapy alone after lumpectomy for select breast cancer: tumor control and survival outcomes of RTOG 95-17.
    Int J Radiat Oncol Biol Phys, 72(2): 467-73. [Abstract] [Full-text]
59. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India.
    J Natl Cancer Inst, 100(18): 1290-300. [Abstract] [Full-text]
60. Human endogenous retrovirus K (HML-2) elements in the plasma of people with lymphoma and breast cancer.
    J Virol, 82(19): 9329-36. [Abstract] [Full-text]
61. Large-core needle biopsy versus fine-needle aspiration biopsy in solid breast lesions: comparison of costs and diagnostic value.
    Acta Radiol, 49(8): 863-9. [Abstract] [Full-text]
62. Localized amyloidosis of the breast associated with invasive lobular carcinoma.
    Br J Radiol, 81(970): e252-4. [Abstract] [Full-text]
63. Identification of cancer care and protocol characteristics associated with recruitment in breast cancer clinical trials.
    J Clin Oncol, 26(27): 4458-65. [Abstract] [Full-text]
64. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.
    J Clin Oncol, 26(27): 4449-57. [Abstract] [Full-text]
65. Tubular carcinoma and grade 1 (well-differentiated) invasive ductal carcinoma: comparison of flat epithelial atypia and other intra-epithelial lesions.
    Pathol Int, 58(10): 620-5. [Abstract] [Full-text]
66. Sonographically guided marker placement for confirmation of removal of mammographically occult lesions after localization.
    AJR Am J Roentgenol, 191(4): 1216-9. [Abstract] [Full-text]
67. Preliminary in vivo validation of a dedicated breast MRI and sonographic coregistration imaging system.
    AJR Am J Roentgenol, 191(4): 1203-7. [Abstract] [Full-text]
68. Complete excision of the MRI target lesion at MRI-guided vacuum-assisted biopsy of breast cancer.
    AJR Am J Roentgenol, 191(4): 1198-202. [Abstract] [Full-text]
69. The antitumor activity of an anti-CD54 antibody in SCID mice xenografted with human breast, prostate, non-small cell lung, and pancreatic tumor cell lines.
    Int J Cancer, 123(10): 2438-45. [Abstract] [Full-text]
70. Glycodelin reduces breast cancer xenograft growth in vivo.
    Int J Cancer, 123(10): 2279-84. [Abstract] [Full-text]
71. Differential subcellular localisation of the tumour suppressor protein LIMD1 in breast cancer correlates with patient survival.
    Int J Cancer, 123(10): 2247-53. [Abstract] [Full-text]
72. KAI1/CD82 is a novel target of estrogen receptor-mediated gene repression and downregulated in primary human breast cancer.
    Int J Cancer, 123(10): 2239-46. [Abstract] [Full-text]
73. Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families.
    BMC Med Genet, 9: 83. [Abstract] [Full-text]
74. Transaxillary retromammary route approach of video-assisted breast surgery enables the inner-side breast cancer to be resected for breast conserving surgery.
    Am J Surg, 196(4): 578-81. [Abstract] [Full-text]
75. Nipple-sparing mastectomy--initial experience at a tertiary center.
    Am J Surg, 196(4): 575-7. [Abstract] [Full-text]
76. Regional variation in breast cancer treatment throughout the United States.
    Am J Surg, 196(4): 572-4. [Abstract] [Full-text]
77. Improvement in sentinel node biopsy results in a teaching community hospital: results of a multidisciplinary quality improvement program.
    Am J Surg, 196(4): 569-71. [Abstract] [Full-text]
78. Do additional shaved margins at the time of lumpectomy eliminate the need for re-excision?
    Am J Surg, 196(4): 556-8. [Abstract] [Full-text]
79. Invasive local recurrence increased after radiation therapy for ductal carcinoma in situ.
    Am J Surg, 196(4): 552-5. [Abstract] [Full-text]
80. Mucinous breast carcinoma: a large contemporary series.
    Am J Surg, 196(4): 549-51. [Abstract] [Full-text]
81. Patient satisfaction and quality of life after MammoSite breast brachytherapy.
    Am J Surg, 196(4): 545-8. [Abstract] [Full-text]
82. Optimal treatment of multiple ipsilateral primary breast cancers.
    Am J Surg, 196(4): 530-6. [Abstract] [Full-text]
83. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
    Am J Surg, 196(4): 527-9. [Abstract] [Full-text]
84. Effectiveness of a noninvasive digital infrared thermal imaging system in the detection of breast cancer.
    Am J Surg, 196(4): 523-6. [Abstract] [Full-text]
85. Impact of neoadjuvant chemotherapy on rate of tissue expander/implant loss and progression to successful breast reconstruction following mastectomy.
    Am J Surg, 196(4): 519-22. [Abstract] [Full-text]
86. Immediate latissimus dorsi miniflap volume replacement for partial mastectomy: use of intra-operative frozen sections to confirm negative margins.
    Am J Surg, 196(4): 512-8. [Abstract] [Full-text]
87. Improved breast cancer survival among hormone replacement therapy users is durable after 5 years of additional follow-up.
    Am J Surg, 196(4): 505-11. [Abstract] [Full-text]
88. Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients.
    Am J Surg, 196(4): 500-4. [Abstract] [Full-text]
89. The survival impact of the choice of surgical procedure after ipsilateral breast cancer recurrence.
    Am J Surg, 196(4): 495-9. [Abstract] [Full-text]
90. A prospective, randomized, controlled, multicenter study of a real-time, intraoperative probe for positive margin detection in breast-conserving surgery.
    Am J Surg, 196(4): 483-9. [Abstract] [Full-text]
91. Do sentinel node micrometastases predict recurrence risk in ductal carcinoma in situ and ductal carcinoma in situ with microinvasion?
    Am J Surg, 196(4): 566-8. [Abstract] [Full-text]
92. Sentinel lymph node biopsy in patients with multicentric/multifocal breast cancer: low false-negative rate and lack of axillary recurrence.
    Am J Surg, 196(4): 562-5. [Abstract] [Full-text]
93. Scientific Impact Recognition Award: Molecular breast imaging: a review of the Mayo Clinic experience.
    Am J Surg, 196(4): 470-6. [Abstract] [Full-text]
94. Scientific Presentation Award: The combination of axillary ultrasound and ultrasound-guided biopsy is an accurate predictor of axillary stage in clinically node-negative breast cancer patients.
    Am J Surg, 196(4): 477-82. [Abstract] [Full-text]
95. Treatment and outcomes of patients with primary breast sarcoma.
    Am J Surg, 196(4): 559-61. [Abstract] [Full-text]
96. Internal mammary sentinel node biopsy for breast cancer.
    Am J Surg, 196(4): 490-4. [Abstract] [Full-text]
97. The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression.
    Mol Cell Biol, 28(19): 5937-50. [Abstract] [Full-text]
98. ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer Cells.
    Endocrinology, 149(10): 4912-20. [Abstract] [Full-text]
99. Biology, prognosis and response to therapy of breast carcinomas according to HER2 score.
    Ann Oncol, 19(10): 1706-12. [Abstract] [Full-text]
100. Prolactin and estrogen up-regulate carboxypeptidase-d to promote nitric oxide production and survival of mcf-7 breast cancer cells.
     Endocrinology, 149(10): 4821-8. [Abstract] [Full-text]
101. Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer.
     Ann Oncol, 19(10): 1669-80. [Abstract] [Full-text]
102. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations.
     Ann Oncol, 19(10): 1713-9. [Abstract] [Full-text]
103. Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study.
     Ann Oncol, 19(10): 1698-705. [Abstract] [Full-text]
104. Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
     Cancer Immunol Immunother, 57(12): 1817-25. [Abstract] [Full-text]
105. Can genes for mammographic density inform cancer aetiology?
     Nat Rev Cancer, 8(10): 812-23. [Abstract] [Full-text]
106. Radiation therapy for operable breast cancer: sixty years of progress as seen through the articles published in the journal Cancer.
     Cancer, 113(7): 1779-800. [Abstract] [Full-text]
107. Breast cancer management: the road to today.
     Cancer, 113(7): 1844-9. [Abstract] [Full-text]
108. Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors.
     Proc Natl Acad Sci U S A, 105(38): 14533-8. [Abstract] [Full-text]
109. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
     Cancer, 113(7): 1666-75. [Abstract] [Full-text]
110. Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer.
     Cancer, 113(7): 1521-6. [Abstract] [Full-text]
111. Clinicopathologic characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution.
     Cancer, 113(7): 1511-20. [Abstract] [Full-text]
112. Comparison of cancer diagnosis and treatment in Medicare fee-for-service and managed care plans.
     Med Care, 46(10): 1108-15. [Abstract] [Full-text]
113. Robust linearized image reconstruction for multifrequency EIT of the breast.
     IEEE Trans Med Imaging, 27(10): 1439-48. [Abstract] [Full-text]
114. Multispectral co-occurrence with three random variables in dynamic contrast enhanced magnetic resonance imaging of breast cancer.
     IEEE Trans Med Imaging, 27(10): 1425-31. [Abstract] [Full-text]
115. Myosin light-chain kinase contributes to the proliferation and migration of breast cancer cells through cross-talk with activated ERK1/2.
     Cancer Lett, 270(2): 312-27. [Abstract] [Full-text]
116. Triptolide inhibits interferon-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells.
     Cancer Lett, 270(2): 337-41. [Abstract] [Full-text]
117. Multigene methylation in serum of sporadic Chinese female breast cancer patients as a prognostic biomarker.
     Oncology, 75(1): 60-6. [Abstract] [Full-text]
118. Clinicopathological features of inflammatory versus noninflammatory locally advanced nonmetastatic breast cancer.
     Tumour Biol, 29(4): 211-6. [Abstract] [Full-text]
119. Involvement of elevated expression of multiple cell-cycle regulator, DTL/RAMP (denticleless/RA-regulated nuclear matrix associated protein), in the growth of breast cancer cells.
     Oncogene, 27(43): 5672-83. [Abstract] [Full-text]
120. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas.
     Am J Surg Pathol, 32(10): 1566-71. [Abstract] [Full-text]
121. Hereditary breast cancer: from molecular pathology to tailored therapies.
     J Clin Pathol, 61(10): 1073-82. [Abstract] [Full-text]
122. Minireview: nuclear receptors and breast cancer.
     Mol Endocrinol, 22(10): 2215-28. [Abstract] [Full-text]
123. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
     J Clin Oncol, 26(28): 4672-8. [Abstract] [Full-text]
124. Psychosocial factors and survival of young women with breast cancer: a population-based prospective cohort study.
     J Clin Oncol, 26(28): 4666-71. [Abstract] [Full-text]
125. The influence of HER2 genotypes as molecular markers on breast cancer outcome.
     DNA Cell Biol, 27(10): 575-9. [Abstract] [Full-text]
126. Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer.
     J Clin Oncol, 26(28): 4679-83. [Abstract] [Full-text]
127. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients.
     J Clin Oncol, 26(28): 4634-8. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.